

# Press Release

## Adcal D3 takes market lead

**Galashiels, Scotland – 12 January 2006** - Adcal D3, ProStrakan's UK-marketed calcium/vitamin D supplement used as an adjunct to specific therapy for osteoporosis, is now the clear market leader in the UK calcium vitamin D market.

According to IMS sales figures for November 2005, Adcal D3 took 34.4% of the market compared with 33.2% taken by its closest single competitor. The product took the lead in terms of volume sales earlier in 2005.

**Commenting, Dr Wilson Totten, ProStrakan CEO, said: "This is an important market for ProStrakan and this degree of success is a major milestone in the development of our UK commercial business. It reflects the wider progress we are making in significantly growing our commercial presence across the EU through organic growth and M&A."**

**ENDS**

### Notes to Editors

#### **Deloitte Award**

When measured by revenue growth over the past 5 years, ProStrakan is the fastest growing healthcare company in Europe, according to the results of the annual Deloitte Technology Fast 500 Award scheme announced in December 2005 (see [www.deloitte.com](http://www.deloitte.com)). Additionally, ProStrakan was judged to be the fastest growing non-IT company in Europe. Between 2000 and 2004, ProStrakan sales grew by 4160 per cent.

**ProStrakan Group plc** is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company's therapeutic focus is on oncology supportive care, bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the Company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are principally handled by commercial subsidiaries based in the UK, France, Germany and Spain.

**Adcal D3 takes market lead, p2**

ProStrakan floated on the London Stock Exchange in June 2005. In September 2005, the Group announced interim results showing revenues up 78% to £16.5 million.

[www.prostrakan.com](http://www.prostrakan.com)

**Enquiries:**

**Dr Wilson Totten, CEO**

**Tel: 01896 664000**

**Adrian Gardner, CFO**

**Tel: 01896 664000**

**David Watt, Corp Comms**

**Tel: 01896 664103**

**ENDS**